Craft

Glenmark Pharmaceuticals

Stock Price

₹1.7 K

2024-10-29

Market Capitalization

₹486.6 B

2024-10-29

Revenue

₹131.5 B

FY, 2025

Glenmark Pharmaceuticals Summary

Company Summary

Overview
Glenmark Pharmaceuticals is a pharmaceutical company that develops and markets branded and generic formulations. It specializes in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). The company focuses on manufacturing niche products across therapeutic areas of dermatology, respiratory, and oncology.
Type
Public
Status
Active
Founded
1977
HQ
Mumbai, IN | view all locations
Website
https://glenmarkpharma.com
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Glenn Saldanha

    Glenn Saldanha, Chairman & Managing Director

    • Cherylann Pinto

      Cherylann Pinto, Executive Director – Corporate Services

      • Cyril Konto

        Cyril Konto, President and Chief Executive Officer – Ichnos Glenmark Innovation

        • V. S. Mani

          V. S. Mani, Executive Director and Global Chief Financial Officer

        LocationsView all

        2 locations detected

        • Mumbai, MH HQ

          India

          B/2, Mahalakshmi Chambers, 22, Bhulabhai Desai Road

        • Mumbai, MH

          India

          Glenmark House, B. D. Sawant Marg, Parshiwada, Kajuwadi, Chakala, Andheri East

        Glenmark Pharmaceuticals Financials

        Summary Financials

        Revenue (Q3, 2026)
        ₹38.9B
        Gross profit (Q3, 2026)
        ₹26.5B
        Net income (Q3, 2026)
        ₹4.0B
        Cash (Q2, 2026)
        ₹26.9B
        EBIT (Q3, 2026)
        ₹5.8B
        Enterprise value
        $471.9B

        Footer menu